Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 Adenocarcinoma of Lung 5 NSCLC 4 Meningeal Carcinomatosis 4 Brain Neoplasms 4 Lung Neoplasms 3 Pleural Effusion, Malignant 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasm, Residual 1 Multiple Primary Lung Cancers 1 EGF-R Positive Non-Small Cell Lung Cancer 1 Carcinoma 1 Adenocarcinoma 1

Interventions

Cisplatin 21 pembrolizumab 16 Gemcitabine 16 Paclitaxel 15 Radiotherapy 14 Carboplatin 14 Radiotherapy, Intensity-Modulated 13 Cyclophosphamide 9 Cetuximab 9 Magnetic Resonance Spectroscopy 8 Radiation 7 padeliporfin 6 Specimen Handling 6 Oxaliplatin 6 Fluorouracil 6 Drug Therapy 6 Docetaxel 6 Capecitabine 6 Bevacizumab 6 anlotinib 5 Nivolumab 5 Irinotecan 5 Erlotinib Hydrochloride 5 Celecoxib 5 poly ICLC 4 fludarabine 4 Standard of Care 4 Sorafenib 4 Leucovorin 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma × aflutinib × Clear all

NCT04401059 2023-12-27

SELECT-2

Hangzhou Normal University

Phase 4 Unknown

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡